BC Extra | Sep 12, 2019
Company News

Management tracks: Vifor, Kintai, Verge, Xellia, Syapse

Vifor Pharma Ltd. (SIX:VIFN) said Sanofi’s Klaus Henning Jensen will become CMO and a member of the executive committee, effective in January. A three-year veteran of the French pharma, Jensen has served as global therapeutic...
BC Extra | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30. He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug also said CFO...
BC Week In Review | Jul 21, 2014
Company News

Fresenius, Novo deal

Xellia Pharmaceuticals, which is wholly owned by Novo, acquired the Raleigh, N.C., freeze-dried vial manufacturing facility of Fresenius’ Fresenius Kabi USA LLC subsidiary. Xellia said it will retain the site’s approximately 80 employees and continue...
BC Week In Review | Jun 24, 2013
Company News

Actavis, Lundbeck, Merck KGaA, Ranbaxy, Xellia Pharmaceuticals A/S, Zoetis neurology news

The European Commission fined H. Lundbeck €93.8 million ($125 million) after ruling that deals with four generic companies for Lundbeck's antidepressant Celexa citalopram violated competition law. The commission said that after Lundbeck's basic patents covering...
BioCentury | Jun 3, 2013
Finance

Seeds to trees

Flush with cash from its existing holdings and not seeing enough worthwhile venture deals to spend it on, Novo A/S has decided to expand its growth equity investments in mature companies. After a proof-of-principle deal...
BC Week In Review | May 27, 2013
Company News

Xellia Pharmaceuticals A/S, Novo A/S deal

*** Xellia Pharmaceuticals A/S , Oslo, Norway   Novo A/S , Hellerup, Denmark   Business: Infectious   Novo will acquire infectious disease company Xellia from private equity firm 3i Group and other shareholders for about $700 million....
BC Extra | May 22, 2013
Company News

Novo A/S acquires Xellia

Novo A/S (Hellerup, Denmark) will acquire infectious disease company Xellia Pharmaceuticals A/S (Oslo, Norway) from private equity firm 3i Group for about $700 million. In 2008, 3i acquired Xellia, which develops and manufactures active pharmaceutical...
BC Week In Review | Mar 4, 2013
Company News

Xellia Pharmaceuticals A/S, SINTEF, Statens Serum Institute deal

Xellia partnered with SINTEF's SINTEF Materials and Chemistry research group and the Statens Serum Institute to develop antibiotics against Gram-negative bacterial infections, including those caused by Pseudomonas, Klebsiella, Acinetobacter and Enterobacter species. The partners received...
BC Extra | Oct 14, 2011
Company News

Cancer Research Technology names Chambre chairman

Cancer Research U.K.'s commercial arm, Cancer Research Technology, appointed Peter Chambre chairman. He succeeds Melanie Lee, who has been chairman since 2003. Chambre is chairman of Xellia Pharmaceuticals A/S (Coppenhagen, Denmark) and 7TM Pharma A/S...
BC Week In Review | Nov 1, 2010
Company News

Affitech management update

Affitech A/S (CSE:AFFI), Copenhagen, Denmark   Business: Antibodies, Cancer, Infectious   Hired: Stig Jarle Pettersen, consultant to Affitech since September 2009, as CFO, formerly CFO of Xellia Pharmaceuticals A/S  ...
Items per page:
1 - 10 of 10
BC Extra | Sep 12, 2019
Company News

Management tracks: Vifor, Kintai, Verge, Xellia, Syapse

Vifor Pharma Ltd. (SIX:VIFN) said Sanofi’s Klaus Henning Jensen will become CMO and a member of the executive committee, effective in January. A three-year veteran of the French pharma, Jensen has served as global therapeutic...
BC Extra | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30. He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug also said CFO...
BC Week In Review | Jul 21, 2014
Company News

Fresenius, Novo deal

Xellia Pharmaceuticals, which is wholly owned by Novo, acquired the Raleigh, N.C., freeze-dried vial manufacturing facility of Fresenius’ Fresenius Kabi USA LLC subsidiary. Xellia said it will retain the site’s approximately 80 employees and continue...
BC Week In Review | Jun 24, 2013
Company News

Actavis, Lundbeck, Merck KGaA, Ranbaxy, Xellia Pharmaceuticals A/S, Zoetis neurology news

The European Commission fined H. Lundbeck €93.8 million ($125 million) after ruling that deals with four generic companies for Lundbeck's antidepressant Celexa citalopram violated competition law. The commission said that after Lundbeck's basic patents covering...
BioCentury | Jun 3, 2013
Finance

Seeds to trees

Flush with cash from its existing holdings and not seeing enough worthwhile venture deals to spend it on, Novo A/S has decided to expand its growth equity investments in mature companies. After a proof-of-principle deal...
BC Week In Review | May 27, 2013
Company News

Xellia Pharmaceuticals A/S, Novo A/S deal

*** Xellia Pharmaceuticals A/S , Oslo, Norway   Novo A/S , Hellerup, Denmark   Business: Infectious   Novo will acquire infectious disease company Xellia from private equity firm 3i Group and other shareholders for about $700 million....
BC Extra | May 22, 2013
Company News

Novo A/S acquires Xellia

Novo A/S (Hellerup, Denmark) will acquire infectious disease company Xellia Pharmaceuticals A/S (Oslo, Norway) from private equity firm 3i Group for about $700 million. In 2008, 3i acquired Xellia, which develops and manufactures active pharmaceutical...
BC Week In Review | Mar 4, 2013
Company News

Xellia Pharmaceuticals A/S, SINTEF, Statens Serum Institute deal

Xellia partnered with SINTEF's SINTEF Materials and Chemistry research group and the Statens Serum Institute to develop antibiotics against Gram-negative bacterial infections, including those caused by Pseudomonas, Klebsiella, Acinetobacter and Enterobacter species. The partners received...
BC Extra | Oct 14, 2011
Company News

Cancer Research Technology names Chambre chairman

Cancer Research U.K.'s commercial arm, Cancer Research Technology, appointed Peter Chambre chairman. He succeeds Melanie Lee, who has been chairman since 2003. Chambre is chairman of Xellia Pharmaceuticals A/S (Coppenhagen, Denmark) and 7TM Pharma A/S...
BC Week In Review | Nov 1, 2010
Company News

Affitech management update

Affitech A/S (CSE:AFFI), Copenhagen, Denmark   Business: Antibodies, Cancer, Infectious   Hired: Stig Jarle Pettersen, consultant to Affitech since September 2009, as CFO, formerly CFO of Xellia Pharmaceuticals A/S  ...
Items per page:
1 - 10 of 10